608 related articles for article (PubMed ID: 11391710)
21. Cellular normoxic biophysical markers of hydroxyurea treatment in sickle cell disease.
Hosseini P; Abidi SZ; Du E; Papageorgiou DP; Choi Y; Park Y; Higgins JM; Kato GJ; Suresh S; Dao M; Yaqoob Z; So PT
Proc Natl Acad Sci U S A; 2016 Aug; 113(34):9527-32. PubMed ID: 27512047
[TBL] [Abstract][Full Text] [Related]
22. Effects of glyceraldehyde on the structural and functional properties of sickle erythrocytes.
Nigen AM; Manning JM
J Clin Invest; 1978 Jan; 61(1):11-9. PubMed ID: 618907
[TBL] [Abstract][Full Text] [Related]
23. Bepridil protects sickle cells against the adverse rheological effects of cyclical deoxygenation.
Johnston MN; Ellory JC; Stuart J
Br J Haematol; 1989 Dec; 73(4):522-6. PubMed ID: 2611138
[TBL] [Abstract][Full Text] [Related]
24. GBT440 improves red blood cell deformability and reduces viscosity of sickle cell blood under deoxygenated conditions.
Dufu K; Patel M; Oksenberg D; Cabrales P
Clin Hemorheol Microcirc; 2018; 70(1):95-105. PubMed ID: 29660913
[TBL] [Abstract][Full Text] [Related]
25. Optical tweezers for measuring red blood cell elasticity: application to the study of drug response in sickle cell disease.
Brandão MM; Fontes A; Barjas-Castro ML; Barbosa LC; Costa FF; Cesar CL; Saad ST
Eur J Haematol; 2003 Apr; 70(4):207-11. PubMed ID: 12656742
[TBL] [Abstract][Full Text] [Related]
26. Importance of methodological standardization for the ektacytometric measures of red blood cell deformability in sickle cell anemia.
Renoux C; Parrow N; Faes C; Joly P; Hardeman M; Tisdale J; Levine M; Garnier N; Bertrand Y; Kebaili K; Cuzzubbo D; Cannas G; Martin C; Connes P
Clin Hemorheol Microcirc; 2016; 62(2):173-9. PubMed ID: 26444610
[TBL] [Abstract][Full Text] [Related]
27. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease.
De Franceschi L; Bachir D; Galacteros F; Tchernia G; Cynober T; Alper S; Platt O; Beuzard Y; Brugnara C
J Clin Invest; 1997 Oct; 100(7):1847-52. PubMed ID: 9312186
[TBL] [Abstract][Full Text] [Related]
28. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
[TBL] [Abstract][Full Text] [Related]
29. Effects of nitric oxide and its congeners on sickle red blood cell deformability.
Belanger AM; Keggi C; Kanias T; Gladwin MT; Kim-Shapiro DB
Transfusion; 2015 Oct; 55(10):2464-72. PubMed ID: 25912054
[TBL] [Abstract][Full Text] [Related]
30. Hemoglobin aggregation and pseudosickling in vitro of hemoglobin Setif-containing erythrocytes.
Noguchi CT; Mohandas N; Blanchette-Mackie J; Mackie S; Raik E; Charache S
Am J Hematol; 1991 Feb; 36(2):131-9. PubMed ID: 2012063
[TBL] [Abstract][Full Text] [Related]
31. Iron nitrosyl hemoglobin formation from the reactions of hemoglobin and hydroxyurea.
Huang J; Hadimani SB; Rupon JW; Ballas SK; Kim-Shapiro DB; King SB
Biochemistry; 2002 Feb; 41(7):2466-74. PubMed ID: 11841242
[TBL] [Abstract][Full Text] [Related]
32. Effects of carbon dioxide and pH variations in vitro on blood respiratory functions, red blood cell volume, transmembrane pH gradients, and sickling in sickle cell anemia.
Ueda Y; Bookchin RM
J Lab Clin Med; 1984 Aug; 104(2):146-59. PubMed ID: 6431043
[TBL] [Abstract][Full Text] [Related]
33. The delay time in sickle cell disease after 40 years: A paradigm assessed.
Ferrone FA
Am J Hematol; 2015 May; 90(5):438-45. PubMed ID: 25645011
[TBL] [Abstract][Full Text] [Related]
34. The effect of ovarian steroids on sickle cell deformability.
Yoong WC; Tuck SM; Yardumian A
Clin Lab Haematol; 1998 Jun; 20(3):151-4. PubMed ID: 9681229
[TBL] [Abstract][Full Text] [Related]
35. Should we still be focused on red cell hemoglobin F as the principal explanation for the salutary effect of hydroxyurea in sickle cell disease?
Segel GB; Simon W; Lichtman MA
Pediatr Blood Cancer; 2011 Jul; 57(1):8-9. PubMed ID: 21480473
[No Abstract] [Full Text] [Related]
36. Erythrocyte heterogeneity in sickle cell disease: effect of deoxygenation on intracellular polymer formation and rheology of sub-populations.
Keidan AJ; Noguchi CT; Player M; Chalder SM; Stuart J
Br J Haematol; 1989 Jun; 72(2):254-9. PubMed ID: 2757967
[TBL] [Abstract][Full Text] [Related]
37. Nitric oxide effects on human erythrocytes structural and functional properties--an in vitro study.
Mesquita R; Piçarra B; Saldanha C; Martins e Silva J
Clin Hemorheol Microcirc; 2002; 27(2):137-47. PubMed ID: 12237483
[TBL] [Abstract][Full Text] [Related]
38. Hydroxyurea and erythropoietin therapy in sickle cell anemia.
Goldberg MA; Brugnara C; Dover GJ; Schapira L; Lacroix L; Bunn HF
Semin Oncol; 1992 Jun; 19(3 Suppl 9):74-81. PubMed ID: 1379376
[TBL] [Abstract][Full Text] [Related]
39. Sickling of nucleated erythroid precursors from patients with sickle cell anemia.
Hasegawa S; Rodgers GP; Dwyer N; Noguchi CT; Blanchette-Mackie EJ; Uyesaka N; Schechter AN; Fibach E
Exp Hematol; 1998 Apr; 26(4):314-9. PubMed ID: 9546314
[TBL] [Abstract][Full Text] [Related]
40. Hydroxyurea-induced oxidative damage of normal and sickle cell hemoglobins in vitro: amelioration by radical scavengers.
Iyamu EW; Fasold H; Roa D; del Pilar Aguinaga M; Asakura T; Turner EA
J Clin Lab Anal; 2001; 15(1):1-7. PubMed ID: 11170226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
